[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580624":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":51,"collaborators":26,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":26,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":26,"enrollmentInfo":63,"targetDuration":26,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":26,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Gangnam Severance Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ropivacaine-Poloxamer 407 hydrogel group","EXPERIMENTAL","Patients withRopivacaine-Poloxamer 407 hydrogel applied to the peritoneal and subcutaneous layers at the incision site.",[13],"Procedure: Arm I (Ropivacaine-Poloxamer 407 hydrogel group)",{"label":15,"type":16,"description":17,"interventionNames":18},"TAP block group","ACTIVE_COMPARATOR","Patients with Ultrasound-guided subcostal TAP block with 0.375% ropivacaine (15 mL per side).",[19],"Procedure: Arm II (TAP block group)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Arm I (Ropivacaine-Poloxamer 407 hydrogel group)","Patients receive intraoperative application of Ropivacaine-Poloxamer 407 hydrogel at the incision site. A mixture of 0.75% Ropivacaine (22.5 mg, 3 mL) and Poloxamer 407-based gel (Welpass, 6 mL) is prepared. The hydrogel is applied as 4 mL between the peritoneum and fascia, and 2 mL is injected subcutaneously around the incision before skin closure. This intervention aims to provide sustained local anesthesia for up to 72 hours.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Arm II (TAP block group)","Patients undergo ultrasound-guided subcostal transversus abdominis plane (TAP) block before anesthesia emergence. A total of 30 mL of 0.375% Ropivacaine (15 mL per side) is injected bilaterally between the internal oblique and transversus abdominis muscles. TAP block is a regional anesthesia technique known for effective postoperative pain control, typically lasting 24 to 48 hours.\n\nBoth groups receive standardized postoperative analgesia, including IV acetaminophen, fentanyl via patient-controlled analgesia (PCA), and rescue pethidine as needed.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"In Gyu Kwon","CONTACT","82-2-2019-4601","gsirb@yuhs.ac",[38],{"facility":5,"status":39,"city":40,"state":26,"zip":26,"country":41,"countryCode":26,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Seoul","South Korea",{"type":43,"coordinates":44},"Point",[45,46],126.9784,37.566,{"lat":46,"lon":45},[49],{"name":50,"role":34,"phone":35,"phoneExt":26,"email":36},"Shiyeol Jun",{"type":52,"investigatorFullName":33,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Assistant Professor","100580624","comparison-of-ropivacaine-poloxamer-407-hydrogel-and-tap-block-for-postoperative-pain-management-in-laparoscopicrobotic-gastrectomy-100580624",false,"NCT06839716","Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic\u002FRobotic Gastrectomy","Prospective Randomized Controlled Study of Ropivacaine-Poloxamer 407 Based Gel Application and TAP Block for Postoperative Pain Management Following Laparoscopic\u002FRobotic Gastrectomy","Inclusion Criteria:\n\n1. Patients with a histologically confirmed diagnosis of gastric adenocarcinoma prior to surgery.\n2. Patients who have undergone a complete surgical resection (R0 resection).\n3. Patients with an ASA (American Society of Anesthesiologists) score of 3 or below.\n4. Patients aged 20 years or older.\n5. Patients who have undergone laparoscopic or robotic gastrectomy\n\nExclusion Criteria:\n\n1. Patients under 19 years of age.\n2. Presence of ascites or peritoneal metastasis.\n3. Patients who have undergone preoperative chemotherapy or radiotherapy.\n4. Diagnosis of malignancies other than gastric cancer.\n5. Uncontrolled diabetes, autoimmune diseases, hypertrophic scars, or keloid history affecting wound healing.\n6. History of allergy or adverse reactions to Ropivacaine or other local anesthetics.\n7. Pregnant women.\n8. Patients with preoperative chronic pain conditions, including CRPS.\n9. Patients with long-term preoperative use of opioid analgesics.\n10. Patients with psychiatric disorders deemed likely to interfere with study participation.\n11. Patients with severe liver disease, renal disease, or arrhythmia.","ALL","20 Years",{"count":64,"type":65},134,"ESTIMATED","INTERVENTIONAL",[68],"NA","This study aims to determine whether Ropivacaine-Poloxamer 407 hydrogel provides non-inferior pain control compared to TAP block for patients undergoing minimally invasive gastrectomy. The results will guide postoperative pain management practices and enhance recovery protocols for gastric cancer surgery.",[71],"Gastric Cancer","2025-02-23",{"date":74,"type":75},"2025-02-25","ACTUAL",{"date":77,"type":75},"2025-02-01",{"date":79,"type":65},"2026-03-31",{"name":5,"class":6},1]